We identified 1276 citations related to gastric cancer/gastroesophageal junction adenocarcinoma; of these, nine reported clinical trial results on tyrosine kinase/VEGF inhibition plus PD-1/PD-L1 inhibition combination in previously treated patients (two phase 1a/1b, two phase 1b, one phase 1/2, four phase 2). This evidence concerns the gene PDCD1 and gastric cancer.